About Us

Intravacc - From discovery to phase II clinical trial

Your specialized CDMO for viral, bacterial, therapeutic, and conjugate vaccines

Based in the Netherlands and nestled within the Utrecht Science Park in Bilthoven, Intravacc is a globally recognized leader in translational vaccinology. With decades of experience, we stand as an independent Contract Development and Manufacturing Organization (CDMO) within the vaccine industry. Our purpose is to serve as the vital link between your discoveries and early-stage clinical trials. We understand that this journey from concept to GMP production is often riddled with challenges, and we specialize in mitigating risks and reducing costs.

The entire team at Intravacc is committed to blazing new paths in vaccine development. We have an exceptional track record imagining and realizing technologies that enable tomorrow’s vaccines. That expertise in vaccine development is at the core of our CDMO services and candidate vaccines out-licensing.

What we do is make vaccines happen

  • We are an independent CDMO offering an all-in-one solution for vaccine development, from design to clinical phase I/II.
  • We provide comprehensive services based on expertise spanning from initial discovery to GMP pilot production for clinical studies.

> Discover our CDMO services...

  • We are the bridge to success, seamlessly connecting research efforts with GMP manufacturing.
  • We are an incubator for cutting-edge technology, including proprietary and patented vaccine production platforms.

> Learn about our production platforms...

  • We have global impact. 30% of childhood vaccines worldwide are based on Bilthoven technology and know-how.

If you are looking for a partner with a global footprint, state-of-the-art facilities, and a team of top-notch vaccine experts, reach out to us. 

Let’s discuss your project.

History

Over a 100 years tradition and innovation in vaccine development

From its early days as the Central Laboratory to its current incarnation as Intravacc B.V., our organization has played a pivotal role in the development and manufacturing of vaccines, making significant contributions to the prevention of infectious diseases in the Netherlands and around the world.

Intravacc’s long history dates to the founding of the Dutch Bacteric Therapeutic Institute in 1894. Over the years, that organization evolved and adapted to become a world leader in vaccine research, development, and manufacturing.

1894
BTI
Bacteric Therapeutic Institute

The Dutch Bacteric Therapeutic Institute was established in 1894 as the Nederlands Vaccin Instituut" in Bilthoven, The Netherlands. Its primary focus was to produce vaccines against bacterial infections, like diphtheria and tuberculosis, that were significant public health threats during that era.

1909
CL
Central Laboratory

The Central Laboratory succeeded the Dutch Therapeutic Institute in 1909. Also founded in Bilthoven, The Netherlands, it had a broader mandate in bacterial research and vaccine development to combat infectious diseases of the time.

1934
RIVM
National Institute for Public Health

The Central Laboratory underwent a name change in 1934 and became the National Institute for Public Health (Rijksinstituut voor Volksgezondheid). The institute continued its work in healthcare research, diagnostics, and vaccine development.

2003
NVI
Netherlands Vaccine Institute

In 2003, the focus of the organization was narrowed to vaccine-related activities. With that new mission came a new name: the Netherlands Vaccine Institute (Nederlands Vaccin Instituut) or NVI. The NVI played a national role in vaccine production and development.

2013
Intravacc
Intravacc founded

As part of a broad government privatization initiative, the NVI was privatized, and the vaccine production facilities were transformed into an autonomous company named Bilthoven Biologics B.V. The research arm of the NVI, including the Animal Research Center (ARC), became a vaccine research institute named Intravacc under the Ministry of Health. The transition into a research institute was a significant milestone in our organization history, though the new institute’s mandate was still vaccine research, process development, and platform optimization. The ARC was acquired by the Poonawalla Science Park in 2019.

2021
Intravacc BV
Private company

While Intravacc has existed as a research institute since 2013, it became a state-owned holding company in 2021. Intravacc B.V. has continued the long tradition and steadfast mission to innovate and advance vaccine research, development, and production.

2024
Intravacc BV
Acquired by FDI

Intravacc has been acquired by First Dutch Innovations (FDI) from the Dutch government. FDI is an investor in Biotech companies and technology companies privatized by TNO, the Dutch Technology Organization.